FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib
Enliven Therapeutics has reached an agreement with the US FDA regarding the final protocol for the ENABLE-2 pivotal Phase III clinical trial evaluating relcobatinib in adults with CML.
The post FDA agrees ENABLE-2 Phase III trial design for Enliven’s relcobatinib appeared first on Clinical Trials Arena .